To this end, we propose strategies such as advancing clinical trials and further exploring large animal models, which will help bridge the gap between preclinical findings and human therapeutic applications
Kalafati M, Jamurtas AZ, Nikolaidis MG, Paschalis V, Theodorou AA, Sakellariou GK, Koutedakis Y, Kouretas D
This can cause chemical pneumonitis, bacterial pneumonia, or airway complications
To view or add a comment, sign in Lilly has officially released Phase 3 data for retatrutide, its triple agonist targeting GIP, GLP-1, and glucagon receptors, marking a significant milestone in the treatment of type 2 diabetes